Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Posted: 12/10/2024 | By: Melissa E. Fryman, MS

The final results of the phase III KEYNOTE-522 trial were recently reported in The New England Journal of Medicine. This report provides results for overall survival in patients with early-stage triple-negative breast cancer who received neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab.

Question 1 of 5

In the phase III KEYNOTE-522 trial, patients with previously untreated stage _ triple-negative breast cancer were randomly assigned in a __ ratio to receive neoadjuvant therapy with pembrolizumab or placebo on top of platinum-containing chemotherapy

Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Posted: 12/10/2024 | By: Melissa E. Fryman, MS

Question 1 of 5

In the phase III KEYNOTE-522 trial, patients with previously untreated stage _ triple-negative breast cancer were randomly assigned in a __ ratio to receive neoadjuvant therapy with pembrolizumab or placebo on top of platinum-containing chemotherapy

Choose 1

CategoriesView All Quizzes

Tumor Type

Additional Topics

Conference Coverage

Posted: 12/10/2024 | By: Melissa E. Fryman, MS

list Quiz Information

Question 1 of 5

In the phase III KEYNOTE-522 trial, patients with previously untreated stage _____ triple-negative breast cancer were randomly assigned in a ______ ratio to receive neoadjuvant therapy with pembrolizumab or placebo on top of platinum-containing chemotherapy

Choose 1

Trending

CategoriesView All Quizzes

Tumor Type

Additional Topics

Conference Coverage

In the phase III KEYNOTE-522 trial, patients with previously untreated stage _ triple-negative breast cancer were randomly assigned in a __ ratio to receive neoadjuvant therapy with pembrolizumab or placebo on top of platinum-containing chemotherapy